Archean Chemical Q1 FY27 Results (NSE: ACI)
Signal: Margin pressure
The read
Q1FY27 consolidated revenue recovered 11.9% YoY to ₹327 Cr but EBITDA margin compressed 570bps to 13.5% — the 8th sequential quarter of margin contraction — as other expenses outpaced sales. PAT fell 24% YoY; standalone results show even steeper operating erosion (OPM down 610bps), partly offset by higher other income. The ₹170 Cr rights infusion into subsidiary Acume Chemicals and the pre-revenue semiconductor subsidiary Sicsem (Fiscal Support Agreement signed) are long-term bets that currently weigh on group profitability.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹3.27 Cr | 11.9% | 8.7% |
| EBIT | ₹0.44 Cr | -23.8% | |
| Net profit | ₹0.3 Cr | -24.4% | |
| EPS | ₹2.48 | -23.7% | |
| EBIT margin | 13.5% |
P&L walk
Consolidated revenue grew 11.9% YoY to ₹327.20 Cr but EBITDA margin collapsed 570bps to 13.5%, the 8th consecutive quarter of margin contraction; PAT fell 24.4% as higher other income could not offset weak operations — the ₹17,000 Lakh rights issue in subsidiary Acume Chemicals distorts earnings quality with subsidiary losses (standalone PAT ₹40.53 Cr vs consolidated PAT ₹30.35 Cr).
Segments
No segment data — the group is single-segment specialty chemicals; subsidiaries (Acume Chemicals, Idealis, Neun Infra, Sicsem) are pre-revenue, dragging consolidated PAT ₹10.18 Cr below standalone (₹40.53 Cr standalone vs ₹30.35 Cr consolidated), largely due to subsidiary losses (₹9.98 Cr combined loss before consolidation adjustments).
Key positives
- Revenue for Q1FY27 at ₹327.20 Cr, +11.9% YoY and +8.7% QoQ, confirms a volume-led recovery from the multi-quarter trough.
- Finance cost flat YoY at ₹5.45 Cr despite the rights issue, indicating manageable debt levels (D/E 0.24 from fundamentals).
- Subsidiary Sicsem entered a Fiscal Support Agreement with India Semiconductor Mission for up to 75% of eligible capex — a potential long-term catalyst.
- Auditor issued unmodified (clean) conclusion on both standalone and consolidated financial results.
Key concerns
- OPM compressed 570bps YoY to 13.5% — 8th consecutive quarter of margin contraction; other expenses grew 23.7% YoY vs revenue 11.9%.
- Consolidated PAT fell 24.4% YoY to ₹30.35 Cr despite revenue growth; standalone PAT (₹40.53 Cr) was 25% higher, dragged by subsidiary losses.
- Other income at ₹5.61 Cr comprised 12.7% of total income; ex-other income, consolidated PBT would have been even weaker.
- Effective tax rate on consolidated rose 60bps YoY to 31.4% as deferred tax credit shrank from ₹1.47 Cr to ₹3.20 Cr.
- Subsidiary Acume Chemicals and pre-revenue units (Idealis, Neun Infra, Sicsem) reported combined net loss of ₹9.98 Cr before consolidation adjustments.
Research and educational content only. Not investment advice.